VP of Business Development, page-19

My response was to m's statement: "They announced pbt2 failed to meet objectives of imagine trial and there are a number of suggestions as to why":

See the above two articles above from Bloomberg's and Motley Fool's journalists' opinions at the time of Prana's announcement of the IMAGINE PBT2 Phase II failure. The fact remains that in the ensuing two years from March 31 2014 to the present there has not been an attempt for another try at testing PBT2 for Alzheimer's. In addition it's nice to have obtained an ODD for Huntington's from the EMA on April 28 2015, but that somewhat common honor has not been put to use.

So - no re-attempt for an Alzheimer's PBT2 trial since 03/31/2014 (except for a Phase II open label extension with incomplete results)
and no Huntington's EMA PBT2 trial with orphan drug designation of 04/28/2015. Why not, except for Prana's inaction?

Of course there were no other clinical trials during that time frame either.